Cantel Medical Corp

Cantel Medical — Investor Presentation (December 2020)

32 slides from Cantel Medical's investor presentation, Dec 10, 2020

  1. Slide 1: Investor Presentation December 2020

    Slide 1: Investor Presentation December 2020

    Investor Presentation December 2020

  2. Slide 2: Leading Global Brands consistently able to grow faster than the market

    Slide 2: Leading Global Brands consistently able to grow faster than the market

    1 Leading Global Brands consistently able to grow faster than the market Cantel is focused on providing solutions for complex reprocessing workflows to prevent healthcare related infections The Leader in Infection Prevention, delivering our Complete Circle of Protection (“CCOP”) solutions in Global

  3. Slide 3: Leveraging Our Fundamental Capabilities Across Channels

    Slide 3: Leveraging Our Fundamental Capabilities Across Channels

    Leveraging Our Fundamental Capabilities Across Channels to Create The Premier Global Infection Prevention and Control Franchise 2 2 Chemistry Sterility Assurance Workflow Efficiency and Compliance PPE Low Cost Manufacturing IP&C Education and Training Track & Trace Only company offering comprehensiv

  4. Slide 4: Cantel Quick Stats

    Slide 4: Cantel Quick Stats

    Cantel Quick Stats 3 1. Pro Forma including the October, 2019 acquisition of Hu-Friedy. 2. Estimated cash generation as a percent of net income post integration of Hu-Friedy. Healthy long-term organic growth outlook of 7%+ Unique portfolio and operational foundation Medical 8%+ Organic Growth Dental

  5. Slide 5: Financial Performance — Track Record of Success

    Slide 5: Financial Performance — Track Record of Success

    $0 $100 $200 $300 $400 $500 $600 $700 $800 $900 $1,000 $1,100 $1,200 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 $ i n m il li o n s 2,3 Financial Performance — Track Record of Success 4 10 Yr. CAGR ~14% ~14% Net Reported Sales Adjusted EBITDAS Organic Growth 4% 12% 6% 11% 9% 11% 8% 4% 4%

  6. Slide 6: Company Highlights

    Slide 6: Company Highlights

    Company Highlights 5 A leading pure-play in the growing $50B global infection prevention & control market with existing businesses in addressable markets of ~$8.5B 1 Uniquely positioned to leverage major trends in the market with a differentiated offering for infection prevention & control challenge

  7. Slide 7: Uniquely Positioned to Leverage Major Trends in the Market

    Slide 7: Uniquely Positioned to Leverage Major Trends in the Market

    COVID-19 resulting in higher IP&C spend per visit across our end-markets COVID-19 accelerating the transition to Ambulatory Surgery Centers (ASC) for elective procedures Uniquely Positioned to Leverage Major Trends in the Market 6 Health systems and providers seeking comprehensive solutions to addre

  8. Slide 8: Cantel 2.0 – Accelerating What's Next

    Slide 8: Cantel 2.0 – Accelerating What's Next

    Expand penetration of procedural products into ASCs Drive greater adoption of complete circle of infection protection Expand penetration of procedural products (PRP) into Europe Accelerate PRP new product pipeline Fast track integration and go-to-market of HuFriedyGroup Deliver consistent performanc

  9. Slide 9: Well Diversified Portfolio of IP&C Businesses

    Slide 9: Well Diversified Portfolio of IP&C Businesses

    Well Diversified Portfolio of IP&C Businesses 8 Consolidated LTM Adj. Operating Profit: $196M1,2,3Consolidated LTM Revenue: $1.06B1 1 (LTM) Last Twelve months ended October 31st, 2020. 2 Before allocation of corporate expenses of ~$39.9M. 3 See appendix for GAAP to Non-GAAP reconciliation.

  10. Slide 10: Medical Segment Overview

    Slide 10: Medical Segment Overview

    Medical Segment Overview 9 Product PortfolioCantel’s Strategic Positioning GI Endoscopy reprocessing workflow leader in North America and Europe with large installed base and leading market share Comprehensive Product Portfolio of capital, chemistry, consumables, and service offering complete soluti

  11. Slide 11: Our Complete Circle of Protection in the Endoscope Reprocessing Cycle

    Slide 11: Our Complete Circle of Protection in the Endoscope Reprocessing Cycle

    Our Complete Circle of Protection Provides Proven Solutions to Deliver Protection at Every Step in the Endoscope Reprocessing Cycle 10 ENDOSCOPY SOLUTIONS WORKFLOW V A L U E A D D E D S E R V IC E S 1 2 3 4 567

  12. Slide 12: Endoscopy Market Dynamics

    Slide 12: Endoscopy Market Dynamics

    Endoscopy Market Dynamics 11 Endoscopy Market Opportunity Over 100M endoscopy procedures in our direct markets growing at low-single digits Colorectal, stomach, and liver cancers continue to be among the top 5 causes of cancer related death US society recommendations to begin CRC screening at age 45

  13. Slide 13: Key Growth Drivers – Medical

    Slide 13: Key Growth Drivers – Medical

    Key Growth Drivers – Medical 12 Increase adoption in new channels and segments Drive deeper penetration into key customer accounts Margin expansion via product mix and full portfolio selling Accelerate product sales via new product introductions • ASC US Commercial Strategy – ASC’s represent 35% of

  14. Slide 14: Dental Segment Overview

    Slide 14: Dental Segment Overview

    Dental Segment Overview 13 Product Portfolio Dental By the Numbers Cantel’s Strategic Positioning Global leading dental brands of Hu-Friedy & Crosstex with enduring customer relationships based on a foundation of quality, innovation, protection, and safety Comprehensive offering of instruments, cons

  15. Slide 15: Our Complete Circle of Prevention – Dental

    Slide 15: Our Complete Circle of Prevention – Dental

    1 Our Complete Circle of Prevention Provides Solutions Tied to Managing the Instrument Lifecycle DENTAL SOLUTIONS WORKFLOW 4 1 2 3 4 567

  16. Slide 16: Dental Market Dynamics

    Slide 16: Dental Market Dynamics

    Dental Market Dynamics 15 Dental Market Opportunity Approx. 200,000 dental professionals in the US in 2019 213 million annual US dental visits growing at 2-3% COVID-19 has heightened awareness of need for best in class IP&C protocols driving compliance and rapid adoption of IP&C solutions US: Instru

  17. Slide 17: Key Growth Drivers – Dental

    Slide 17: Key Growth Drivers – Dental

    Key Growth Drivers – Dental 16 New Product Introductions Enhanced Focus on Education & Training Drive Adoption of Expanded Portfolio Enhanced Partnerships Expanded product sales from new products Market growth driven by increased IP&C education Grow Share of Wallet Premium position driven by custome

  18. Slide 18: Life Sciences Segment Overview

    Slide 18: Life Sciences Segment Overview

    Life Sciences Segment Overview 17 Product Portfolio Installed Base Centrals Portables US Dialysis Clinics >30,000 annual service visits >5,500 >15,000 85% Strategic Positioning Leading hemodialysis water filtration technology with four decades of peracetic acid and chemistry expertise Only national

  19. Slide 19: Capital Allocation Priorities

    Slide 19: Capital Allocation Priorities

    Capital Allocation Priorities 18 Enhanced R&D and product innovation investments Organic Growth Ongoing strategic investments in commercial initiatives 1 Strong cash flow generation supports potential to significantly de-lever Debt Paydown Maintain strong and flexible balance sheet 2 Pursue continue

  20. Slide 20: Poised for Continued Growth and Margin Improvement

    Slide 20: Poised for Continued Growth and Margin Improvement

    Poised for Continued Growth and Margin Improvement 19 A leading pure-play in the growing $50B global infection prevention & control market with existing businesses in addressable markets of ~$8.5B 1 Uniquely positioned to leverage major trends in the market with a differentiated offering for infecti

  21. Slide 21: Cantel

    Slide 21: Cantel

    S CANTEL

  22. Slide 22: Forward Looking Statements

    Slide 22: Forward Looking Statements

    Forward Looking Statements 21 This press release contains “forward-looking statements” as that term is defined under the Private Securities Litigation Reform Act of 1995 and other securities laws. For these statements, we claim the protection of the safe harbor for forward-looking statements contain

  23. Slide 23: GAAP to Non-GAAP EPS Disclosure

    Slide 23: GAAP to Non-GAAP EPS Disclosure

    GAAP to Non-GAAP EPS Disclosure 22 Non-GAAP financial measures contained herein supplement information previously reported in filings on Form 10-Q and Form 10-K as well as in presentations by Company management to investors, analysts and others. The information below will not be deemed “filed” for p

  24. Slide 24: GAAP to Non-GAAP EPS Disclosure (continued)

    Slide 24: GAAP to Non-GAAP EPS Disclosure (continued)

    GAAP to Non-GAAP EPS Disclosure (continued) 23 (c) Non-GAAP Income from Operations, Non-GAAP Net Income and Non-GAAP Diluted EPS We define non-GAAP income from operations, as income from operations adjusted to exclude (i) amortization of purchased intangible assets, (ii) acquisition-related items, (

  25. Slide 25: GAAP to Non-GAAP EPS Disclosure (continued)

    Slide 25: GAAP to Non-GAAP EPS Disclosure (continued)

    GAAP to Non-GAAP EPS Disclosure (continued) 24 Excess tax benefits (expenses) Excess tax benefits and expenses resulting from stock compensation are recorded as an adjustment to income tax expense. The magnitude of the impact of excess tax benefits generated in the future, which may be favorable or

  26. Slide 26: GAAP to Non-GAAP EPS Disclosure (continued)

    Slide 26: GAAP to Non-GAAP EPS Disclosure (continued)

    GAAP to Non-GAAP EPS Disclosure (continued) 25 Other Adjustments During fiscal 2019, we recorded specific discrete tax items associated with our international operations that were unrelated to fiscal 2019. As we believe that these items were not representative of our normal effective tax rate, we ex

  27. Slide 27: Historical P&L

    Slide 27: Historical P&L

    Historical P&L 26 ($ in millions, except per share data) Fiscal Year Ending 7/31/2020 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 Net Sales $273.9 $321.7 $386.5 $425.0 $488.7 $565.0 $665.0 $770.2 $871.9 $918.2 $1,016.0 Gross Profit Gross Margin $110.9 38.3% $122.8 38.2% $164.2 42.5% $183.

  28. Slide 28: Balance Sheet & Cash Flow

    Slide 28: Balance Sheet & Cash Flow

    Balance Sheet & Cash Flow 27 1. Net Debt calculated as Gross Debt minus cash on balance sheet. 2. See appendix for GAAP to Non-GAAP reconciliation. 3. Earnings before Interest, Taxes, Depreciation, Amortization, Stock compensation expense, (Gain)/Loss on Disposal of Fixed Asset, Acquisition-related

  29. Slide 29: GAAP to Non-GAAP EPS Reconciliation

    Slide 29: GAAP to Non-GAAP EPS Reconciliation

    Fiscal Year 2020 Ending 7/31/2020 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 GAAP Diluted EPS1 $0.52 $0.52 $0.77 $0.95 $1.04 $1.15 $1.44 $1.71 $2.18 $1.32 $0.32 + Intangible amortization $0.08 $0.10 $0.15 $0.16 $0.16 $0.21 $0.22 $0.30 $0.32 $0.39 $0.59 + Acquisition related items $0.00 $

  30. Slide 30: Income to Adjusted EBITDAS Reconciliation

    Slide 30: Income to Adjusted EBITDAS Reconciliation

    Income to Adjusted EBITDAS Reconciliation 29 1. *The effect of rounding may create minor data variances. ($ in millions) Fiscal Year 2020 Ending 7/31/2020 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 Net Income $19.9 $20.4 $31.3 $39.2 $43.3 $48.0 $60.0 $71.4 $91.0 $55.0 $13.7 + Income taxe

  31. Slide 31: Segment Operating Profit to Adj. Operating Profit Reconciliation

    Slide 31: Segment Operating Profit to Adj. Operating Profit Reconciliation

    Segment Operating Profit to Adj. Operating Profit Reconciliation 30 1. *The effect of rounding may create minor data variances. ($ in millions) (LTM) Last Twelve Months Ending 10/31/2020 Medical Life Sciences Dental Dialysis HQ Consol Income from operations, as reported $61.7 $27.8 $23.7 $8.4 $(37.4

  32. Slide 32: Gross Debt to Net Debt Reconciliation

    Slide 32: Gross Debt to Net Debt Reconciliation

    Gross Debt to Net Debt Reconciliation 31 1. FY11 Net Debt includes $98M in debt assumed on the first day of fiscal year 2012 upon closing of the Byrne Medical acquisition. 2. FY20 Net Debt includes Hu-Friedy acquisition debt from October 2019 along with $168M of convertible notes issued in May 2020

Source: SEC EDGAR · 8-K filed Dec 10, 2020

More decks from Cantel Medical Corp